Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Spinal Cord Series and Cases (2)
Neuropsychopharmacology (1)
Nature Medicine (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (4)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Diseases
Drug discovery
Health care
Medical research

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–4 of 4 results

Advanced filters: Author: Tracy Ransom Clear advanced filters

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial

As presented at the ESMO Congress 2025: In patients with locally advanced or metastatic solid tumours, including mesothelioma, treatment with a first-in-class inhibitor of the Hippo−YAP−TEAD pathway was safe and led to encouraging clinical response rates in patients with mesothelioma.

Timothy A. Yap
David J. Kwiatkowski
Hedy L. Kindler
Research19 Oct 2025
Nature Medicine

Volume: 31, P: 4281-4290
Attitudes toward and knowledge of medical cannabis among individuals with spinal cord injury

Michael Stillman
Michael Mallow
Daniel Graves
Research18 Jan 2019
Spinal Cord Series and Cases

Volume: 5, P: 1-5
Utilization of medicinal cannabis for pain by individuals with spinal cord injury

Michael Stillman
Maclain Capron
Daniel Graves
Research10 Jul 2019
Spinal Cord Series and Cases

Volume: 5, P: 1-8
A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence

Megan L Ryan
Daniel E Falk
Raye Z Litten
Research23 Sept 2016
Neuropsychopharmacology

Volume: 42, P: 1012-1023

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

Search

Filter By:

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial

Attitudes toward and knowledge of medical cannabis among individuals with spinal cord injury

Utilization of medicinal cannabis for pain by individuals with spinal cord injury

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence

Search

Quick links